This conclusion is due to the fact that most studies reported controversial results regarding the effects of SGLT2 on bone metabolism, yet factors such as age, co-morbidities, gender and, most importantly, the time/duration of treatments were not taken into account; these variables are crucial in the case of metabolic bone diseases such as osteoporosis. This evidence concerns the gene SLC5A2 and osteoporosis.